Gracell Biotech's Multiple Myeloma Candidate Shows 100% Response Rate In Newly Diagnosed Candidates

Gracell Biotechnologies Inc GRCL announced the clinical data from its ongoing Phase 1 investigator-initiated trial (IIT) in China evaluating GC012F as first-line therapy in transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM) patients.
Patients in the study achieved a 100% overall response rate (ORR) and 100% minimal residual disease (MRD) negativity in all dose levels.
Related: Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims.
Among the 16 evaluable patients with a median follow-up time of eight months. 100% of evaluable patients achieved MRD negativity in all dose levels.
100% of patients experienced robust CAR-T cell expansion with long persistence in all dose levels
The clinical data also demonstrated a favorable safety profile.
25% (4/16) of patients experienced Grade 1-2 cytokine release syndrome (CRS); no patients experienced Grade 3-5 CRS
No immune effector cell-associated neurotoxicity syndrome or other neurotoxicity of any grade had been observed.
Price Action: GRCL shares are down 3.39% at $2.43 on the last check Monday.